Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat.

    Apr 30, 2026DOI: 10.1093/cid/ciaf520Journal ArticleCID

    Written by: Ciarra LeocadioElizabeth A GarciaMaura LashJonathan BerardiJustin ChanRachel ChasanBlanca EsquivelMary FooteMarshall J GlesbyAmiyah GuerraAlexander B HarrisDorothy KnutsenSharon MannheimerDana MazoJacob McLeanTristan D McPhersonEric A MeyerowitzOfole MgbakoGopi PatelPatricia M Pagán PiralloAsa E RadixPaul F RiskaMark N SayeghLeah SeifuRaphael ShawBarry S ZingmanRustin ZomorodiJason ZuckerMarcia Wong

    Find these authors on Roon

    TM

    Dr. Tristan McPherson

    General ID · NYU Langone

    OM

    Dr. Ofole Mgbako

    HIV/AIDS Medicine · NYU Langone

    Summary

    BACKGROUND: There is emerging literature describing clinical characteristics and outcomes in patients with mpox treated with tecovirimat.METHODS: We analyzed retrospective deidentified data from healthcare systems in New York City with the highest number of tecovirimat prescriptions. Individuals with probable or confirmed mpox initiating tecovirimat from May to December 2022 were included. A chart abstraction instrument was used to extract demographic and clinical data from medical records. We examined factors associated with delay in treatment and hospitalization.RESULTS: A total of 708 individuals prescribed tecovirimat for mpox were included in the analysis; median age was 36 years (IQR 31-43); 566 (80%) were cisgender men who have sex with men; and 399 (56%) were diagnosed with HIV. Side effects (100, 14%) and severe adverse events (7, 1%) were rare. The most common long-term sequela was scarring (69, 10%). One hundred and one (14%) were hospitalized. Median time from symptom onset to treatment initiation was 8 days (IQR 6-11). Non-Hispanic Black patients had higher risk of initiating tecovirimat ≥8 days after symptom onset (relative risk [RR] = 1.3, 95% CI: 1.2-1.7) and being hospitalized (adjusted relative risk [aRR] = 2.2, 95% CI: 1.4-3.5) compared with Hispanic patients, after adjusting for HIV and insurance status.CONCLUSIONS: We described common reasons for tecovirimat initiation and hospitalization. There were racial inequities in hospitalization and treatment delays. More research and focused efforts to mitigate these inequities are needed. These findings may better inform decisions for treatment initiation and hospitalization for mpox.
    OMDr. Ofole Mgbako
    Leading Voice

    Dr. Ofole Mgbako

    Infectious Disease · HIV & AIDS Medicine
    NYU Langone Health
    ofole